Ind-Swift Laboratories Ltd. (INDSWFTLAB) Price & Analysis

Compare

0 Followers

INDSWFTLAB Stock Chart & Stats

₹90.70

-₹2.17(-1.99%)

At close: Jan 08 4:00 PM EST

₹90.70

-₹2.17(-1.99%)

Day’s Range― - ―

52-Week Range₹67.15 - ₹150.00

Previous CloseN/A

Volume31.71K

Average Volume (3M)7.30K

Market Cap

₹11.59B

Enterprise Value₹7.80B

Total Cash (Recent Filing)₹4.67B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)3.8

Beta1.40

Next Earnings

Jun 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.17

Shares Outstanding81,611,560

10 Day Avg. Volume7,859

30 Day Avg. Volume7,299

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)0.46

Price to Sales (P/S)0.96

P/FCF Ratio-5.97

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue GrowthSustained top-line expansion of ~25% demonstrates growing demand for the company’s products and services. Over the next 2–6 months this durable momentum should support operating leverage, capacity utilization and reinvestment ability, reinforcing market position in generics and contract manufacturing.

Balance Sheet StrengthExtremely low leverage combined with a high ROE provides durable financial flexibility to fund capex, R&D or targeted M&A without large new borrowing. This structural strength reduces default risk, supports strategic optionality and helps the firm withstand near-term cash volatility.

Diversified Business ModelMultiple revenue streams across APIs, finished formulations, contract manufacturing and exports diversify customer concentration and geographies. This structural diversification reduces single-market exposure, stabilizes revenues across cycles and enhances the firm’s ability to capture global generic demand over months to years.

Bears Say

Weak Cash GenerationNegative operating and free cash flows indicate poor cash conversion despite reported revenues and earnings. Over the medium term this can constrain working capital, limit self‑funded investments, and force reliance on external financing or asset sales, weakening strategic flexibility.

Margin Compression At EBITA negative EBIT margin signals that core operations are not covering operating costs before non-operating items. Persisting margin pressure undermines sustainable profitability, raises dependence on non‑operating gains, and risks impaired ability to absorb input cost inflation or price competition over coming quarters.

Earnings TrajectoryNegative EPS growth reflects deteriorating bottom-line momentum and may stem from margin stress, one-offs or operational issues. If EPS contraction continues, the company’s capacity to reinvest, pay stakeholders, and build reserve cushions will be impaired, affecting medium‑term financial resilience.

Ind-Swift Laboratories Ltd. News

Ind-Swift Labs Files CARE Monitoring Report on Rs 314.6 Crore Preferential Issue

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) has shared an announcement. Ind-Swift Laboratories Ltd. has disclosed that CARE Ratings...

19d ago

Ind-Swift Laboratories Closes Trading Window Ahead of Q3 FY2025 Results

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) just unveiled an update. Ind-Swift Laboratories Ltd. has announced the closure of...

2M ago

Ind-Swift Laboratories Completes Intra-Promoter Transmission of 232,057 Shares

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) has issued an update. Ind-Swift Laboratories Ltd. has informed the stock exchanges...

2M ago

Ind-Swift Laboratories Secures Trading Approval for New Equity Shares Post-Amalgamation

An announcement from Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) is now available. Ind-Swift Laboratories Ltd. has received trading...

3M ago

Ind-Swift Laboratories Announces 30th AGM and Annual Report Availability

An update from Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) is now available. Ind-Swift Laboratories Ltd. has announced the...

6M ago

Ind-Swift Laboratories Announces Major Share Allotment Amid Amalgamation

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) just unveiled an update. Ind-Swift Laboratories Ltd. has announced the allotment of...

6M ago

Ind-Swift Laboratories Announces Financial Results and Share Allotment Post-Merger

An update from Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) is now available. Ind-Swift Laboratories Ltd. announced the approval...

6M ago

Ind-Swift Laboratories Ensures Compliance with SEBI Regulations

An announcement from Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) is now available. Ind-Swift Laboratories Ltd. has submitted a...

8M ago

INDSWFTLAB FAQ

What was Ind-Swift Laboratories Ltd.’s price range in the past 12 months?

Ind-Swift Laboratories Ltd. lowest stock price was ₹67.15 and its highest was ₹150.00 in the past 12 months.

What is Ind-Swift Laboratories Ltd.’s market cap?

Ind-Swift Laboratories Ltd.’s market cap is ₹11.59B.

When is Ind-Swift Laboratories Ltd.’s upcoming earnings report date?

Ind-Swift Laboratories Ltd.’s upcoming earnings report date is Jun 03, 2026 which is in 101 days.

How were Ind-Swift Laboratories Ltd.’s earnings last quarter?

Ind-Swift Laboratories Ltd. released its earnings results on Jan 31, 2026. The company reported ₹1.169 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.169.

Is Ind-Swift Laboratories Ltd. overvalued?

According to Wall Street analysts Ind-Swift Laboratories Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ind-Swift Laboratories Ltd. pay dividends?

Ind-Swift Laboratories Ltd. pays a Annually dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Ind-Swift Laboratories Ltd. dividends here

What is Ind-Swift Laboratories Ltd.’s EPS estimate?

Ind-Swift Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ind-Swift Laboratories Ltd. have?

Ind-Swift Laboratories Ltd. has 81,611,560 shares outstanding.

What happened to Ind-Swift Laboratories Ltd.’s price movement after its last earnings report?

Ind-Swift Laboratories Ltd. reported an EPS of ₹1.169 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.07%.

Which hedge fund is a major shareholder of Ind-Swift Laboratories Ltd.?

Currently, no hedge funds are holding shares in IN:INDSWFTLAB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Ind-Swift Laboratories Ltd.

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.